Report ID: SQSG35G2015
In-Vitro Diagnostics Market Size, Share, Growth Analysis, By Product (Reagents & Kits, Instruments), By Technology (Immunoassays, Clinical Chemistry), By Specimen, By Test Type, By Application, By End User, By Region - Industry Forecast 2025-2032
Report ID:
SQSG35G2015 |
Region:
Global |
Published Date: December, 2024
Pages:
157
|
Tables:
124 |
Figures:
77
In-Vitro Diagnostics Market Competitive Landscape
Investing in the research and development of advanced in-vitro diagnostics solutions will be a top priority for all market players. Increasing affordability of in-vitro diagnostics tests should also be a key focus for in-vitro diagnostics providers. Launching new in-vitro diagnostics products and tests will help companies stay competitive and stand out in the global market. Providing favorable reimbursement for in-vitro diagnostics will also be a crucial aspect for business expandion in the long run.
Top Player’s Company Profilesin In-Vitro Diagnostics Industry
- Roche
- Siemens Healthineers
- Thermo Fisher Scientific
- Abbott Laboratories
- bioMérieux
- Bio-Rad Laboratories
- QIAGEN
- Agilent Technologies
- Sysmex Corporation
- Fujifilm Holdings
- Illumina
- Shimadzu Corporation
- DiaSorin
- Grifols
- Quest Diagnostics
- Transasia Bio-Medicals
- Tulip Diagnostics
- NeoDx
- Voxtur Bio
- Peerless Biotech
In-Vitro Diagnostics Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONFAQs
In-Vitro Diagnostics Market size was valued at USD 87.93 Billion in 2023 and is poised to grow from USD 92.59 Billion in 2024 to USD 139.94 Billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).
Investing in the research and development of advanced in-vitro diagnostics solutions will be a top priority for all market players. Increasing affordability of in-vitro diagnostics tests should also be a key focus for in-vitro diagnostics providers. Launching new in-vitro diagnostics products and tests will help companies stay competitive and stand out in the global market. Providing favorable reimbursement for in-vitro diagnostics will also be a crucial aspect for business expandion in the long run. 'Roche ', 'Siemens Healthineers ', 'Thermo Fisher Scientific ', 'Abbott Laboratories ', 'bioMérieux ', 'Bio-Rad Laboratories ', 'QIAGEN ', 'Agilent Technologies ', 'Sysmex Corporation ', 'Fujifilm Holdings ', 'Illumina ', 'Shimadzu Corporation ', 'DiaSorin ', 'Grifols ', 'Quest Diagnostics ', 'Transasia Bio-Medicals ', 'Tulip Diagnostics ', 'NeoDx ', 'Voxtur Bio ', 'Peerless Biotech '
The prospect of home care is becoming more attractive and common worldwide. In-vitro diagnostics companies can focus on the development of test kits that can be used at home easily without medical supervision to maximize their revenue generation and capitalize on the growing popularity of homecare around the world.
The presence of developed healthcare infrastructure and key diagnostics providers allows North America to hold a dominant market share. Growing investments in R&D of novel diagnostics and the rising popularity of homecare in this region are also expected to boost sales of in-vitro diagnostics products in the future. Favorable regulatory environment and rising adoption of advanced diagnostics technologies are making the United States a key market for in-vitro diagnostics companies operating in North America.
Request Free Customization
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
USA (+1) 351-333-4748
